ישראל - עברית - Ministry of Health

teva medical marketing ltd. - ascorbic acid; biotin; colecalciferol; cyanocobalamin; dexpanthenol; folic acid; nicotinamide; phytomenadione; pyridoxine (vit b6) hydrochloride; riboflavine; thiamine (vit b1) hydrochloride; tocopherol (vit e) (as tocopheryl acetate); vitamin a palmitate - תוסף לתמיסה לאינפוזיה - ascorbic acid 80 mg / 4 ml; vitamin a palmitate 2300 iu / 4 ml; colecalciferol 400 iu / 4 ml; thiamine (vit b1) hydrochloride 1.2 mg / 4 ml; riboflavine 1.4 mg / 4 ml; nicotinamide 17 mg / 4 ml; pyridoxine (vit b6) hydrochloride 1 mg / 4 ml; dexpanthenol 5 mg / 4 ml; tocopherol (vit e) (as tocopheryl acetate) 7 iu / 4 ml; phytomenadione 0.2 mg / 4 ml; folic acid 140 mcg/ml; biotin 20 mcg/ml; cyanocobalamin 1 mcg/ml - multivitamins and other minerals, incl. combinations - multivitamins and other minerals, incl. combinations - for use as a multiple vitamin supplement for infants and children up to 11 years of age. it is also indicated in other situations where there are increased requirements for vitamins due to stress situations such as surgery, extensive burns, fractures and other trauma, severe infectious diseases, and comatose states. the physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. the use of a multivitamin product obviates the need to speculate on the status of individual vitamin nutriture.

ישראל - עברית - Ministry of Health

sanofi israel ltd - agalsidase beta - אבקה להכנת תמיסה מרוכזת לעירוי - agalsidase beta 35 mg/vial - agalsidase beta - agalsidase beta - fabrazyme is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of fabry disease. (alfa - galactosidase a deficiency).

ישראל - עברית - Ministry of Health

cure medical & technical supply - sodium chloride 9 g/l; starch etherified 60 g/l - solution for infusion - other plasma protein fractions - therapy and prophylaxis of hypovolaemia and shock in connection with surgery, trauma.

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited, israel - ipilimumab - תרכיז להכנת תמיסה לאינפוזיה - ipilimumab 5 mg/ml - ipilimumab - ipilimumab - yervoy (ipilimumab) is indicated for the treatment of unresectable or metastatic melanoma.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate; salmeterol as xinafoate - אבקה לשאיפה - fluticasone propionate 100 mcg; salmeterol as xinafoate 50 mcg - salmeterol and other drugs for obstructive airway diseases - salmeterol and other drugs for obstructive airway diseases - seretide is indicated in the regular treatment of severe and moderate reversible obstructive airways disease ( road) , including asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate; salmeterol as xinafoate - אבקה לשאיפה - fluticasone propionate 500 mcg; salmeterol as xinafoate 50 mcg - salmeterol and other drugs for obstructive airway diseases - salmeterol and other drugs for obstructive airway diseases - seretide is indicated in the regular treatment of severe and moderate reversible obstructive airways disease ( road) , including asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate. extension of copd indication for seretide diskus:seretide is indicated for the symptomatic treatment of patients with copd, with a fev1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate; salmeterol as xinafoate - אבקה לשאיפה - fluticasone propionate 250 mcg; salmeterol as xinafoate 50 mcg - salmeterol and other drugs for obstructive airway diseases - salmeterol and other drugs for obstructive airway diseases - seretide is indicated in the regular treatment of severe and moderate reversible obstructive airways disease ( road) , including asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate. extension of copd indication for seretide diskus:seretide is indicated for the symptomatic treatment of patients with copd, with a fev1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.

ישראל - עברית - Ministry of Health

rekah pharmaceutical industry ltd, israel - bacitracin; neomycin as sulfate; polymyxin b sulfate - משחה לעין - bacitracin 400 u/g; polymyxin b sulfate 5000 u/g; neomycin as sulfate 5 mg/g - antibiotics in combination with other drugs - antibiotics in combination with other drugs - short term treatment of superficial external ocular infections caused by organisms susceptible to one or more of the antibiotics contained therein.

ישראל - עברית - Ministry of Health

sanofi israel ltd - sevelamer carbonate anhydrous - טבליות מצופות פילם - sevelamer carbonate anhydrous 800 mg - sevelamer - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ? 1.78 mmol/l.should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

ישראל - עברית - Ministry of Health

sanofi israel ltd - sevelamer carbonate anhydrous - אבקה להכנת תרחיף - sevelamer carbonate anhydrous 2.4 g/sachet - sevelamer - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.also indicated for the control of hyperphosphataemia in adult patients with chronic kidney diseasenot on dialysis with serum phosphorus ? 1.78 mmol/l.should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.